Details for New Drug Application (NDA): 040888
✉ Email this page to a colleague
NDA 040888 describes METHYLPREDNISOLONE SODIUM SUCCINATE, which is a drug marketed by Abraxis Pharm, Amneal, Bedford Labs, Elkins Sinn, Eugia Pharma, Fresenius Kabi Usa, Hikma, Intl Medication, Sagent Pharms Inc, Teva Parenteral, Tianjin Kingyork, and Watson Labs, and is included in thirty-three NDAs. It is available from eight suppliers. Additional details are available on the METHYLPREDNISOLONE SODIUM SUCCINATE profile page.
The generic ingredient in METHYLPREDNISOLONE SODIUM SUCCINATE is methylprednisolone sodium succinate. There is one drug master file entry for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the methylprednisolone sodium succinate profile page.
The generic ingredient in METHYLPREDNISOLONE SODIUM SUCCINATE is methylprednisolone sodium succinate. There is one drug master file entry for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the methylprednisolone sodium succinate profile page.
Summary for 040888
| Tradename: | METHYLPREDNISOLONE SODIUM SUCCINATE |
| Applicant: | Sagent Pharms Inc |
| Ingredient: | methylprednisolone sodium succinate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 40MG BASE/VIAL | ||||
| Approval Date: | Jul 18, 2011 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 125MG BASE/VIAL | ||||
| Approval Date: | Jul 18, 2011 | TE: | AP | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500MG BASE/VIAL | ||||
| Approval Date: | Jul 18, 2011 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
